Recent news releases
-
Jun 9, 2026 Apotex Health Corp. upsizes its initial public offering
-
Jun 1, 2026 Apotex Health Corp. launches its initial public offering
-
May 28, 2026 Apotex Health Corp. files preliminary prospectus for initial public offering
-
May 26, 2026 Apotex expands ophthalmic portfolio with Health Canada approval of IHEEZO™
-
May 14, 2026 Apotex launches Apo-Semaglutide Injection™, a generic equivalent of Ozempic®, in Canada
-
May 1, 2026 Apotex becomes the first Canadian-based global pharmaceutical company to receive Health Canada approval for a generic equivalent of Ozempic®
-
Apr 23, 2026 Apotex Announces Strategic Transaction with Cumberland Pharmaceuticals to Integrate their U.S. Branded Businesses
-
Apr 7, 2026 Apotex Strengthens Osteoporosis Care in Canada with Health Canada's Approval of DENOZA™, a Denosumab Biosimilar
-
Mar 30, 2026 Apotex announces leadership changes
-
Mar 25, 2026 Apotex Expands Canadian Ophthalmology Portfolio with Health Canada’s Approval of CLOBIVIS™ (Clobetasol Propionate Ophthalmic Suspension, 0.05%)